Literature DB >> 22624719

SnapShot: glioblastoma multiforme.

Svetlana Kotliarova1, Howard A Fine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22624719     DOI： 10.1016/j.ccr.2012.04.031

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  17 in total

1.  Long Intergenic Non-Protein Coding RNA 1094 Promotes Initiation and Progression of Glioblastoma by Promoting microRNA-577-Regulated Stabilization of Brain-Derived Neurotrophic Factor.

Authors:  Xiaoyan Dong; Xiuxin Fu; Miao Yu; Zengfen Li
Journal:  Cancer Manag Res       Date:  2020-07-09       Impact factor: 3.989

Review 2.  Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer.

Authors:  Christoph Plass; Stefan M Pfister; Anders M Lindroth; Olga Bogatyrova; Rainer Claus; Peter Lichter
Journal:  Nat Rev Genet       Date:  2013-10-09       Impact factor: 53.242

3.  MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.

Authors:  Wei Yan; Yanwei Liu; Pei Yang; Zheng Wang; Yongping You; Tao Jiang
Journal:  Oncotarget       Date:  2015-05-10

4.  NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma.

Authors:  Hui Wang; Jian-Qing Pan; Lun Luo; Xin-Jie Ning; Zhuo-Peng Ye; Zhe Yu; Wen-Sheng Li
Journal:  Mol Cancer       Date:  2015-02-11       Impact factor: 27.401

5.  Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.

Authors:  Monica Patanè; Paola Porrati; Elisa Bottega; Sara Morosini; Gabriele Cantini; Vita Girgenti; Ambra Rizzo; Marica Eoli; Bianca Pollo; Francesca L Sciacca; Serena Pellegatta; Gaetano Finocchiaro
Journal:  Mol Cancer       Date:  2013-12-11       Impact factor: 27.401

6.  Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.

Authors:  Ying Mao; Yu Yao; Li-Wei Zhang; Yi-Cheng Lu; Zhong-Ping Chen; Jian-Min Zhang; Song-Tao Qi; Chao You; Ren-Zhi Wang; Shu-Yuan Yang; Xiang Zhang; Ji-Sheng Wang; Ju-Xiang Chen; Qun-Ying Yang; Hong Shen; Zhi-Yong Li; Xiang Wang; Wen-Bin Ma; Xue-Jun Yang; Hai-Ning Zhen; Liang-Fu Zhou
Journal:  Chin Med J (Engl)       Date:  2015-10-20       Impact factor: 2.628

7.  Redox-Related Epigenetic Mechanisms in Glioblastoma: Nuclear Factor (Erythroid-Derived 2)-Like 2, Cobalamin, and Dopamine Receptor Subtype 4.

Authors:  Matthew Scott Schrier; Malav Suchin Trivedi; Richard Carlton Deth
Journal:  Front Oncol       Date:  2017-03-30       Impact factor: 6.244

8.  The invasive proteome of glioblastoma revealed by laser-capture microdissection.

Authors:  Thomas Daubon; Joris Guyon; Anne-Aurélie Raymond; Benjamin Dartigues; Justine Rudewicz; Zakaria Ezzoukhry; Jean-William Dupuy; John M J Herbert; Frédéric Saltel; Rolf Bjerkvig; Macha Nikolski; Andreas Bikfalvi
Journal:  Neurooncol Adv       Date:  2019-09-28

Review 9.  FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment.

Authors:  Chengcheng Liao; Jiaxing An; Suqin Yi; Zhangxue Tan; Hui Wang; Hao Li; Xiaoyan Guan; Jianguo Liu; Qian Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

10.  Deregulated expression of TANK in glioblastomas triggers pro-tumorigenic ERK1/2 and AKT signaling pathways.

Authors:  J Stellzig; A Chariot; K Shostak; S Ismail Göktuna; F Renner; T Acker; A Pagenstecher; M L Schmitz
Journal:  Oncogenesis       Date:  2013-11-11       Impact factor: 7.485
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.